Resources
14 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 11/17/2023 (updated 3/28/2024)
The Bureau of Justice Assistance (BJA), Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP), and Advocates for Human Potential, Inc. (AHP) has provided a curated resource list for corrections officers and other jail staff members manage the well-being of individuals in jail custody who have SUD. The categories of resources were prioritized by participants in a jail practitioner roundtable on opioid-related training needs convened by the Bureau of Justice Assistance.
Posted 4/26/2022 (updated 3/27/2024)
Overview of the jail-based Medication Assisted Treatment program within the Adult Detention Center in Fairfax County, Virginia.
Posted 4/6/2022 (updated 3/27/2024)
County jails and community organizations across Michigan are teaming up on a new approach to distribute naloxone (Narcan®), the lifesaving medication used to reverse an opioid overdose, through the use of customized vending machines.
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 4/1/2021 (updated 4/5/2024)
This webinar will introduce attendees to the infrastructure, implementation, impact and adaptation of Regrounding. Our Response, a statewide effort to address stigma through collective impact underway in Maryland and being adapted in West Virginia. Structured around 5 curriculum areas, each addressing a persistent myth instrumental in upholding stigma related SUD/OUD, the content is delivered within the state at no cost by one of the 25 master presenters trained from across regions and sectors—a process being captured by the Association of State and Territorial Health Officers, who are producing a toolkit that is forthcoming.
Posted 3/25/2021 (updated 4/5/2024)
Recovery Housing, Medications for OUD (MOUD), and Emerging Issues
Presenters will explain recovery housing and MOUD in the context of issues emerging in rural America resulting from the pandemic and its impact on the rates of substance use disorder (SUD) and drug overdose. They will discuss the impact of the pandemic on the correctional system and state actions in response to COVID-19 as it affects those with SUD. They will also give an overview of how recovery housing can be developed, especially in rural areas.
Posted 3/3/2021 (updated 4/5/2024)
The National Governors Association and the American Correctional Association recently released a new toolkit on "Expanding Access to Medications for Opioid Use Disorder in Corrections and Community Settings: A Roadmap for States to Reduce Opioid Use Disorder for People in the Justice System."
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications. The following are key steps for supporting MOUD in corrections settings.
Posted 6/26/2020 (updated 3/28/2024)
This report provides recommendations for actions that state and local leaders can take immediately to increase evidence-based practices, decrease arbitrary determinations, and prevent overdose deaths. The report also provides concrete steps that will, in the longterm, help dismantle a siloed system of unequal access and disparities and move towards an integrated system that promotes restorative justice, where people and families are treated with dignity, and where addiction is treated as a health and wellness matter rather than one of moral failing or criminality.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.